About: Multi-system Inflammatory Syndrome in Children & Adolescents (MIS-C): A Systematic Review of Clinical features and presentation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multi-system Inflammatory Syndrome in Children & Adolescents (MIS-C): A Systematic Review of Clinical features and presentation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Multi-system Inflammatory Syndrome in Children & Adolescents (MIS-C): A Systematic Review of Clinical features and presentation
Creator	Cook, James Gupta, Atul Harman, Katharine Radia, Trisha Agrawal, Pankaj Weale, Jonathan Williams, Nia
source	Elsevier; PMC
abstract	Multisystem Inflammatory Syndrome in Children (MIS-C) is a new phenomenon reported worldwide with temporal association with Covid-19. The objective of this paper is to evaluate reported cases in children and adolescents. From 1726 papers, 35 documented papers related to MIS-C cases identified 783 individual cases of MIS-C between March-June 2020; with 55% being male (n=435) and a median age of 8.6 years (IQR,7-10 years; range 3 months-20 years). Patients with MIS-C were noted to have a high frequency of gastrointestinal symptoms (71%) including abdominal pain (34%) and diarrhea (27%). Cough and respiratory distress were reported in 4.5% and 9.6% cases respectively. Blood parameters showed neutrophilia in 345/418 (83%) of cases and a high CRP in 587/626 (94%). 362/619 (59%) cases were SARS-CoV-2 infection positive (serology or PCR) however only 41% demonstrated pulmonary changes on chest imaging. Severity of illness was high with 68% cases requiring intensive care admission; 63% requiring inotropic support; 244/783 (28%) cases needing some form of respiratory support (138 mechanically ventilated), and 31 required extra-corporeal membrane oxygenation. Treatment strategies included intravenous immunoglobulin (63%) and intravenous steroids (44%). 29 cases received Infliximab, 47 received IL1 (interleukin) receptor antagonist, and 47 received IL6- receptor antagonist. 12/783 (1.5%) children died. In summary, a higher incidence of gastrointestinal symptoms were noted in MIS-C. In contrast to acute Covid-19 infection in children, MIS-C appears to be a condition of higher severity with 68% of cases having required critical care support.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1016/j.prrv.2020.08.001
has license	no-cc
schema:url	https://doi.org/10.1016/j.prrv.2020.08.001
resource representing a document's title	Multi-system Inflammatory Syndrome in Children & Adolescents (MIS-C): A Systematic Review of Clinical features and presentation
has PubMed Central identifier	PMC7417920
schema:publication	Paediatr Respir Rev
resource representing a document's body	covid:PMC7417920#body_text
is schema:about of	named entity 'Review' named entity 'Inflammatory' named entity 'Clinical features' named entity 'Cardiovascular dysfunction' named entity 'extracorporeal membranous oxygenation' named entity 'cough' named entity 'biochemical' named entity 'WHO' named entity 'cardiac involvement' named entity 'MIS' named entity 'neutrophilia' named entity 'Kawasaki disease' named entity 'sars-cov-2' named entity 'Brain Natriuretic Peptide' named entity 'RT-PCR' named entity 'respiratory failure' named entity 'WHO' named entity 'Europe' named entity 'clinical features' named entity 'Anakinra' named entity 'fever' named entity 'physiological' named entity 'causal link' named entity 'MIS-C' named entity 'clinical presentation' named entity 'Troponin' named entity 'antigen test' named entity 'infective agent' named entity 'adverse side effects' named entity 'MIS-C' named entity 'MIS-C' named entity 'MIS-C' named entity 'fever' named entity 'SARS-CoV-2' named entity 'echocardiographic' named entity 'coronavirus disease' named entity 'fever' named entity 'Covid-19' named entity 'therapeutic strategies' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'Rashes' named entity 'lymphopenia' named entity 'SARS-CoV-2' named entity 'diarrhoea' named entity 'gastrointestinal problems' named entity 'cutaneous' named entity 'asymptomatic carriage' named entity 'neonate' named entity 'lung parenchyma' named entity 'echocardiograms' named entity 'inflammatory response' named entity 'WHO' named entity 'MAS' named entity 'inflammation' named entity 'Cardiovascular dysfunction' named entity 'C-reactive protein' named entity 'SARS-CoV-2 virus' named entity 'NT-proBNP' named entity 'infection' named entity 'WHO' named entity 'C-reactive protein' named entity 'sars' named entity 'aneurysms' named entity 'MIS' named entity 'CYP' named entity 'streptococcal' named entity 'Asian' named entity 'non-invasive ventilation' named entity 'infection' named entity 'MIS' named entity 'data extraction' named entity 'heterogeneity' named entity 'hypotensive' named entity 'MIS-C' named entity 'ECMO' named entity 'RT-PCR' named entity 'coronavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software